21 results
·
23ms
·
Sources: EU EUDAMED, US FDA
Filters
Regulation: Us FDA
×
LipiView II Ocular Surface Interferometer
FDA 510(k)
FDA Class 2
·Ophthalmic
MILAGRO INTERFERENCE SCREWS
FDA 510(k)
FDA Class 2
·Orthopedic
EASYPROPHY SERIES AIR POLISH DEVICES, MODELS EASYPROPHY 200 AND EASYPROPHY 400
FDA 510(k)
FDA Class 1
·Dental
INFUSE BONE GRAFT
FDA Adverse Event
Injury
·MEDTRONIC SOFAMOR DANEK USA, INC·Product code NEK·October 8, 2014
VIRTUOSO DR
FDA Adverse Event
Injury
·IPG MFG SWITZERLAND·Product code LWS·June 8, 2013
FLAIR ENDOVASCULAR STENT GRAFT
FDA Adverse Event
Malfunction
·BARD PERIPHERAL VASCULAR, INC.·Product code MIH·June 28, 2011
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 25, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 25, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 25, 2024
MERGE HEMO
FDA Adverse Event
Malfunction
·MERGE HEALTHCARE·Product code DQK·September 24, 2024
ELEKTA LIMITED Elekta Synergy Platform, REF MRT 8501, MRT 8511; Medical Charged-Particle Radiation Therapy System Accelerator, Linear
FDA Enforcement
Class II
·Ongoing·Elekta, Inc.·December 13, 2023
SL & SLi Series (Mod 15/18/20/25) Linear Accelerator Used for radiation therapy treatments of malignant neoplastics diseases.
FDA Enforcement
Class II
·Terminated·Elekta, Inc.·March 26, 2014